Newsweek, June 27, 2009
Ten years ago, the human genome was medicine’s holy grail. Playing the part of King Arthur’s knights were rival teams of biologists racing to sequence all the genetic instructions required to make a human being. And just as the actual Holy Grail was believed to have miraculous healing powers, some promised that the genome would change medicine forever. Biotech companies raced to cash in—Human Genome Sciences, for instance, filed patents on 100,000 genes and, in 1999, saw its stock quadruple. But genomic science didn’t deliver fast breakthroughs. Today Human Genome’s stock price is down below $3, and its vast patent portfolio looks like overkill, considering that a human has only about 20,000 genes altogether.